HomeCompareBLLB vs PFE

BLLB vs PFE: Dividend Comparison 2026

BLLB yields 285714.29% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLLB wins by $1.734986541242196e+31M in total portfolio value
10 years
BLLB
BLLB
● Live price
285714.29%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.734986541242196e+31M
Annual income
$17,337,928,197,276,910,000,000,000,000,000,000,000.00
Full BLLB calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — BLLB vs PFE

📍 BLLB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLLBPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLLB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLLB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLLB
Annual income on $10K today (after 15% tax)
$24,285,714.29/yr
After 10yr DRIP, annual income (after tax)
$14,737,238,967,685,373,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, BLLB beats the other by $14,737,238,967,685,373,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLLB + PFE for your $10,000?

BLLB: 50%PFE: 50%
100% PFE50/50100% BLLB
Portfolio after 10yr
$8.67493270621098e+30M
Annual income
$8,668,964,098,638,455,000,000,000,000,000,000,000.00/yr
Blended yield
99.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BLLB
No analyst data
Altman Z
-761.5
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLLB buys
0
PFE buys
0
No recent congressional trades found for BLLB or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLLBPFE
Forward yield285714.29%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1.734986541242196e+31M$51.1K
Annual income after 10y$17,337,928,197,276,910,000,000,000,000,000,000,000.00$27,210.54
Total dividends collected$1.734908400352195e+31M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BLLB vs PFE ($10,000, DRIP)

YearBLLB PortfolioBLLB Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$28,582,129$28,571,428.57$9,161$701.38+$28.57MBLLB
2$76,351,353,429$76,320,770,551.21$8,610$859.79+$76351.34MBLLB
3$190,619,493,207,524$190,537,797,259,355.30$8,366$1,081.25+$190619493.20MBLLB
4$444,781,927,427,195,200$444,577,964,569,463,100.00$8,483$1,405.66+$444781927427.19MBLLB
5$969,967,353,346,567,200,000$969,491,436,684,220,000,000.00$9,084$1,907.24+$969967353346567.13MBLLB
6$1,976,961,629,315,093,000,000,000$1,975,923,764,247,012,300,000,000.00$10,418$2,732.78+$1976961629315092992.00MBLLB
7$3,765,923,944,594,039,000,000,000,000$3,763,808,595,650,671,000,000,000,000.00$13,007$4,193.56+$3.765923944594039e+21MBLLB
8$6,704,681,437,057,684,000,000,000,000,000$6,700,651,898,436,968,000,000,000,000,000.00$18,010$7,005.87+$6.704681437057683e+24MBLLB
9$11,156,275,836,497,016,000,000,000,000,000,000$11,149,101,827,359,364,000,000,000,000,000,000.00$28,216$12,979.89+$1.1156275836497015e+28MBLLB
10$17,349,865,412,421,960,000,000,000,000,000,000,000$17,337,928,197,276,910,000,000,000,000,000,000,000.00$51,081$27,210.54+$1.734986541242196e+31MBLLB

BLLB vs PFE: Complete Analysis 2026

BLLBStock

Bell Buckle Holdings, Inc. produces all-natural products. It offers pure cane sugar, whole fruits and berries, and fresh produce. The company, through its subsidiaries, provides all-natural fruit jams, including strawberry, peach, raspberry, blackberry, blueberry, and cherry jams; instant drink mixes, such as spiced tea and cocoa mocha; fruit pecan pepper jellies, salad dressings, dessert toppings, wine jellies, vanillas, glazes and sauces, hot sauces, specialties, and salsas; traditional pickles; and cappuccino. It offers its products online. Bell Buckle Holdings, Inc. was formerly known as Digital Color Print Inc. and changed its name to Bell Buckle Holdings, Inc. in June 2007. Bell Buckle Holdings, Inc. was founded in 1995 and is based in Naples, Florida.

Full BLLB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BLLB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLLB vs SCHDBLLB vs JEPIBLLB vs OBLLB vs KOBLLB vs MAINBLLB vs JNJBLLB vs MRKBLLB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.